Volume 19, Number 10—October 2013
Human Infection with Eurasian Avian-like Influenza A(H1N1) Virus, China
|Age group, y||Antigen||Increase ≥4, %‡||Geometric mean titer
|Before vac.||After vac.||Before vac.||After vac.||Before vac.||After vac.|
|Children, n = 25||A/California/7/2009||60.0||21.1||121.3||44.0||84.0||16.0||60.0|
|Adults, n = 30||A/California/7/2009||70.0||14.8||156.3||26.7||76.7||0||60.0|
|Elderly adults, n = 30||A/California/7/2009||46.7||10.5||52.8||10.0||53.3||0||30.0|
†All children received 2 doses of vaccine with an interval of 1 month. The composition of the trivalent vaccine were A/Christchurch/16/2010(NIB-74xp) (A/California/7/2009-like), A/Victoria/361/2011 (H3N2)IVR-165, and B/Hubei-Wujiagang/158/2009. Serum samples were obtained from vaccine recipients living in northern (children) and southern (adults and elderly adults) China.
‡Increase in antibody titer.
1These authors contributed equally to this article.
- Page created: September 17, 2013
- Page last updated: September 17, 2013
- Page last reviewed: September 17, 2013
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)